Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA
- PMID: 11451695
- PMCID: PMC90652
- DOI: 10.1128/AAC.45.8.2348-2353.2001
Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA
Abstract
Clostridium difficile is the etiological agent of antibiotic-associated colitis and the most common cause of hospital-acquired infectious diarrhea. Fluoroquinolones such as ciprofloxacin are associated with lower risks of C. difficile-associated diarrhea. In this study, we have analyzed 72 C. difficile isolates obtained from patients with different clinical courses of disease, such as toxic megacolon and relapses; the hospital environment; public places; and horses. They were investigated for their susceptibilities to moxifloxacin (MXF), metronidazole (MEO), and vancomycin (VAN). Mutants highly resistant to fluoroquinolones were selected in vitro by stepwise exposure to increasing concentrations of MXF. The resulting mutants were analyzed for the presence of mutations in the quinolone resistance-determining regions of DNA gyrase (gyrA), the production of toxins A and B, and the epidemiological relationship of these isolates. These factors were also investigated using PCR-based methods. All strains tested were susceptible to MEO and VAN. Twenty-six percent of the clinical isolates (19 of 72) were highly resistant to MXF (MIC > or = 16 microg/ml). Fourteen of these 19 strains contained nucleotide changes resulting in amino acid substitutions at position 83 in the gyrA protein. Resistant strains selected in vitro did not contain mutations at that position. These findings indicate that resistance to MXF in a majority of cases may be due to amino acid substitution in the gyrA gene.
Figures


Similar articles
-
High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.J Antimicrob Chemother. 2006 Dec;58(6):1264-7. doi: 10.1093/jac/dkl398. Epub 2006 Oct 3. J Antimicrob Chemother. 2006. PMID: 17018563
-
Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates.Diagn Microbiol Infect Dis. 2010 Apr;66(4):419-24. doi: 10.1016/j.diagmicrobio.2009.12.002. Diagn Microbiol Infect Dis. 2010. PMID: 20226332
-
Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea.Anaerobe. 2009 Dec;15(6):244-8. doi: 10.1016/j.anaerobe.2009.09.009. Epub 2009 Oct 8. Anaerobe. 2009. PMID: 19818865
-
Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.Antimicrob Agents Chemother. 2001 Aug;45(8):2263-8. doi: 10.1128/AAC.45.8.2263-2268.2001. Antimicrob Agents Chemother. 2001. PMID: 11451683 Free PMC article.
-
Bacterial resistance to fluoroquinolones: lessons to be learned.Infection. 1994;22 Suppl 2:S140-7. doi: 10.1007/BF01793579. Infection. 1994. PMID: 7927833 Review.
Cited by
-
Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.Antimicrob Agents Chemother. 2005 Feb;49(2):488-92. doi: 10.1128/AAC.49.2.488-492.2005. Antimicrob Agents Chemother. 2005. PMID: 15673722 Free PMC article.
-
In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.Antimicrob Agents Chemother. 2003 Nov;47(11):3667-71. doi: 10.1128/AAC.47.11.3667-3671.2003. Antimicrob Agents Chemother. 2003. PMID: 14576144 Free PMC article.
-
Changes in Clostridium (Clostridioides) difficile PCR-Ribotype Distribution and Antimicrobial Resistance in a German Tertiary Care Hospital Over the Last 10 Years.Curr Microbiol. 2019 Apr;76(4):520-526. doi: 10.1007/s00284-019-01654-3. Epub 2019 Feb 25. Curr Microbiol. 2019. PMID: 30805700
-
gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027.Emerg Infect Dis. 2007 Mar;13(3):504-5. doi: 10.3201/eid1303.060771. Emerg Infect Dis. 2007. PMID: 17552115 Free PMC article. No abstract available.
-
Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms.Biomed Res Int. 2018 Feb 21;2018:8414257. doi: 10.1155/2018/8414257. eCollection 2018. Biomed Res Int. 2018. PMID: 29682562 Free PMC article. Review.
References
-
- Ackermann G, Schaumann R, Pless B, Claros M C, Goldstein E J C, Rodloff A C. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 2000;19:228–232. - PubMed
-
- Banno Y, Kobayashi T, Kono H, Watanabe K, Veno K, Nozawa Y. Biochemical characterisation and biological action of two toxins (D-1 and D-2) from Clostridium difficile. Rev Infect Dis. 1984;6:S11–S20. - PubMed
-
- Brosius J, Dull T J, Sleeter D D, Noller H F. Gene organization and primary structure of a ribosomal RNA operon from Escherichia coli. J Mol Biol. 1981;148:107–127. - PubMed
-
- Cambau E, Gutmann L. Mechanisms of resistance to quinolones. Drugs. 1993;45:15–23. - PubMed
-
- Cohen S H, Tang Y J, Muenzner J, Gumerlock P H, Silva J., Jr Isolation of various genotypes of Clostridium difficile from patients and the environment in an oncology ward. Clin Infect Dis. 1996;24:889–893. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases